4D-310 Market Summary

Key Factors Driving 4D-310 Growth

1. Potential cardiac targeting and direct enzyme production

4D-310 was designed to deliver the GLA gene directly to cardiomyocytes, the muscle cells of the heart, using its engineered C102 AAV vector. Fabry-related cardiomyopathy is a major cause of disease burden and mortality. Direct enzyme production in affected heart tissue could differentiate 4D-310 from conventional enzyme replacement therapy, which has limitations in treating cardiac disease.

2. Promising early cardiac outcomes

In February 2024, 4D Molecular Therapeutics reported interim results from six treated adults, with five evaluable for cardiac endpoints. All five showed clinically meaningful improvement in at least one measure of cardiac function, exercise capacity or cardiac-related quality of life over 12–24 months. A cardiac biopsy from one patient also demonstrated gene delivery, enzyme expression and clearance of Gb3 substrate in cardiomyocytes. These findings were encouraging but came from a very small, uncontrolled study.

3. Substantial enzyme-expression results

In the October 2021 interim analysis of three patients, serum AGA activity reached normal or above-normal levels in all patients, including one with high pre-treatment anti-AGA antibody titres. Two patients reached approximately 21-fold and 25-fold the mean normal enzyme activity. Sustained enzyme production could support a one-time treatment model and reduce dependence on repeated ERT infusions, if durable benefit is confirmed.

4. Potential to reduce treatment burden

A single intravenous administration was intended to provide lasting enzyme production, potentially replacing ERT infusions typically given every two weeks. This could reduce treatment visits and improve convenience for patients with lifelong Fabry disease. However, this benefit remains hypothetical because 4D-310 has not been approved and its long-term benefit–risk profile remains uncertain.

5. Regulatory engagement and potential development pathway

4D-310 received FDA Fast Track designation in August 2020. In October 2023, the company announced FDA alignment on a plan to address the U.S. clinical hold, including a revised protocol with rituximab and sirolimus immunosuppression to reduce the risk of atypical hemolytic uremic syndrome (aHUS). This illustrates a possible route to further development, but it does not mean the program has resumed or that approval is imminent.

4D-310 Recent Developments

4DMT has explicitly stated that future clinical development or new IND activations for 4D-310 will require third-party partnerships or dedicated asset-specific funding.

“4D-310 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of 4D-310 for potential indication like Fabry’s disease in the 7MM. A detailed picture of 4D-310’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the 4D-310 for potential indications. The 4D-310 market report provides insights about 4D-310’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current 4D-310 performance, future market assessments inclusive of the 4D-310 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of 4D-310 sales forecasts, along with factors driving its market.

4D-310 Drug Summary

4D-310 is an investigational gene therapy developed by 4D Molecular Therapeutics for the treatment of Fabry disease, a rare, inherited X-linked lysosomal storage disorder caused by mutations in the GLA gene that result in deficient alpha-galactosidase A (α-Gal A) enzyme activity and the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in organs such as the heart, kidneys and blood vessels. The therapy uses a proprietary, engineered adeno-associated virus (AAV) vector, known as 4D-C102, to deliver a functional copy of the human GLA gene into cells, enabling them to produce α-Gal A. Following a single intravenous infusion, 4D-310 is designed to achieve sustained enzyme activity in the bloodstream while also promoting local enzyme production in affected tissues, particularly cardiac muscle, potentially enabling the clearance of accumulated substrates and addressing Fabry-associated cardiomyopathy. Its gene-replacement approach could offer a longer-lasting alternative to conventional enzyme replacement therapy, which requires repeated infusions. 4D-310 has been evaluated in Phase I/II clinical trials, including the INGLAXA studies, assessing its safety, tolerability, enzyme activity and potential effects on cardiac function. Early clinical findings reported increased α-Gal A activity and encouraging signals in cardiac imaging and functional assessments. However, development has faced important safety challenges, including cases of atypical hemolytic uremic syndrome (aHUS), a potentially serious complication that led to pauses in enrollment and clinical holds while the company investigated risk-mitigation strategies, including immunosuppressive treatment and revised patient-selection criteria. The report provides 4D-310’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the 4D-310 Market Report

The report provides insights into:

• A comprehensive product overview including the 4D-310 MoA, description, dosage and administration, research and development activities in potential indication like Fabry’s disease.
• Elaborated details on 4D-310 regulatory milestones and other development activities have been provided in 4D-310 market report.
• The report also highlights 4D-310‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The 4D-310 market report also covers the patents information, generic entry and impact on cost cut.
• The 4D-310 market report contains current and forecasted 4D-310 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The 4D-310 market report also features the SWOT analysis with analyst views for 4D-310 in potential indications.

Methodology

The 4D-310 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

4D-310 Analytical Perspective by DelveInsight

• In-depth 4D-310 Market Assessment

This 4D-310 sales market forecast report provides a detailed market assessment of 4D-310 for potential indication like Fabry’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted 4D-310 sales data uptil 2034.

• 4D-310 Clinical Assessment

The 4D-310 market report provides the clinical trials information of 4D-310 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

4D-310 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

4D-310 Market Potential & Revenue Forecast

• Projected market size for the 4D-310 and its key indications
• Estimated 4D-310 sales potential (4D-310 peak sales forecasts)
• 4D-310 Pricing strategies and reimbursement landscape

4D-310 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• 4D-310 Market positioning compared to existing treatments
• 4D-310 Strengths & weaknesses relative to competitors

4D-310 Regulatory & Commercial Milestones

• 4D-310 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

4D-310 Clinical Differentiation

• 4D-310 Efficacy & safety advantages over existing drugs
• 4D-310 Unique selling points

4D-310 Market Report Highlights

• In the coming years, the 4D-310 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The 4D-310 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence 4D-310’s dominance.
• Other emerging products for Fabry’s disease are expected to give tough market competition to 4D-310 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of 4D-310 in potential indications.
• Analyse 4D-310 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted 4D-310 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of 4D-310 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of 4D-310? How strong is 4D-310’s clinical and commercial performance?
• What is 4D-310’s clinical trial status in each individual indications such as Fabry’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the 4D-310 Manufacturers?
• What are the key designations that have been granted to 4D-310 for potential indications? How are they going to impact 4D-310’s penetration in various geographies?
• What is the current and forecasted 4D-310 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of 4D-310 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to 4D-310 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is 4D-310? What is the duration of therapy and what are the geographical variations in cost per patient?